Renaissance Technologies LLC Acquires 78,600 Shares of INmune Bio, Inc. (NASDAQ:INMB)

Renaissance Technologies LLC increased its holdings in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 73.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 185,800 shares of the company's stock after purchasing an additional 78,600 shares during the period. Renaissance Technologies LLC owned approximately 0.84% of INmune Bio worth $868,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Wells Fargo & Company MN boosted its position in INmune Bio by 51.0% during the fourth quarter. Wells Fargo & Company MN now owns 6,377 shares of the company's stock valued at $30,000 after buying an additional 2,155 shares during the period. Geode Capital Management LLC boosted its holdings in INmune Bio by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 363,602 shares of the company's stock valued at $1,698,000 after acquiring an additional 19,136 shares during the period. Diametric Capital LP grew its position in INmune Bio by 24.6% during the 4th quarter. Diametric Capital LP now owns 36,699 shares of the company's stock worth $171,000 after acquiring an additional 7,244 shares during the last quarter. JPMorgan Chase & Co. lifted its position in INmune Bio by 93.0% in the fourth quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock valued at $53,000 after purchasing an additional 5,461 shares during the last quarter. Finally, LPL Financial LLC lifted its position in INmune Bio by 33.0% in the fourth quarter. LPL Financial LLC now owns 19,072 shares of the company's stock valued at $89,000 after purchasing an additional 4,730 shares during the last quarter. Institutional investors own 12.72% of the company's stock.

INmune Bio Stock Performance

Shares of NASDAQ INMB traded up $0.00 during midday trading on Wednesday, hitting $7.13. 195,621 shares of the company traded hands, compared to its average volume of 253,502. INmune Bio, Inc. has a 12-month low of $4.32 and a 12-month high of $11.47. The firm has a market cap of $163.92 million, a P/E ratio of -3.27 and a beta of 1.63. The stock has a 50-day moving average price of $7.72 and a 200 day moving average price of $6.83.

INmune Bio (NASDAQ:INMB - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported ($0.40) earnings per share for the quarter, topping analysts' consensus estimates of ($0.54) by $0.14. As a group, equities analysts expect that INmune Bio, Inc. will post -2.24 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages recently commented on INMB. Maxim Group lifted their target price on shares of INmune Bio from $22.00 to $30.00 and gave the stock a "buy" rating in a research note on Thursday, February 13th. Scotiabank upped their price objective on shares of INmune Bio from $22.00 to $23.00 and gave the company a "sector outperform" rating in a research note on Tuesday, February 11th. Rodman & Renshaw began coverage on INmune Bio in a research note on Tuesday, January 28th. They issued a "buy" rating and a $23.00 target price on the stock. Finally, RODMAN&RENSHAW raised INmune Bio to a "strong-buy" rating in a research report on Tuesday, January 28th. Five investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, INmune Bio presently has a consensus rating of "Buy" and an average target price of $22.80.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.